Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesAmortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Verastem (VSTM) EBT (2018 - 2025)

Historic EBT for Verastem (VSTM) over the last 8 years, with Q3 2025 value amounting to -$39.9 million.

  • Verastem's EBT fell 670.74% to -$39.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$158.2 million, marking a year-over-year decrease of 5240.1%. This contributed to the annual value of -$130.5 million for FY2024, which is 4931.5% down from last year.
  • Latest data reveals that Verastem reported EBT of -$39.9 million as of Q3 2025, which was down 670.74% from -$43.2 million recorded in Q2 2025.
  • Over the past 5 years, Verastem's EBT peaked at -$15.0 million during Q1 2021, and registered a low of -$43.4 million during Q1 2025.
  • Its 5-year average for EBT is -$24.8 million, with a median of -$20.2 million in 2023.
  • Over the last 5 years, Verastem's EBT had its largest YoY gain of 6043.43% in 2021, and its largest YoY loss of 27343.58% in 2021.
  • Verastem's EBT (Quarter) stood at -$16.5 million in 2021, then fell by 1.94% to -$16.8 million in 2022, then fell by 20.18% to -$20.2 million in 2023, then plummeted by 57.34% to -$31.8 million in 2024, then decreased by 25.45% to -$39.9 million in 2025.
  • Its EBT stands at -$39.9 million for Q3 2025, versus -$43.2 million for Q2 2025 and -$43.4 million for Q1 2025.